Allogene Soars On ALPHA3 Trial Data

April 13, 2026 — 09:24 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Shares of Allogene Therapeutics, Inc. (ALLO) are up over 50% at $4.32 today, following data from the planned interim futility analysis of its pivotal, randomized Phase 2 ALPHA3 trial in first-line (1L) consolidation large B-cell lymphoma (LBCL).

ALPHA3 is a pivotal Phase 2 study evaluating first-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma who have minimal residual disease after responding to standard therapy.

According to the trial results, Cemacabtagene ansegedleucel (cema-cel) showed strong activity in first-line consolidation for large B-cell lymphoma, with 58.3% of patients achieving minimal residual disease (MRD) clearance compared to 16.7% in the observation group.

Enrollment in the phase 2 ALPHA3 trial is expected to be completed by the end of 2027, with an interim event-free survival (EFS) analysis planned for mid-2027 and the primary EFS readout expected in mid-2028.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Allogene Soars On ALPHA3 Trial Data

Tags

Latest Articles